Protocol Ledger

NCT07045311 · Phase II · RECRUITING

JS207 Combination Therapy in Triple-negative Breast Cancer

Interventional Phase II clinical trial protocol NCT07045311 sponsored by Shanghai Junshi Bioscience Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-09-17 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07045311
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07045311
Protocol FieldVerified Registry Value
NCT IdentifierNCT07045311
Consolidated Lead SponsorShanghai Junshi Bioscience Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2025-09-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI